AI in Colonoscopy Gets Calmer, More Transparent to Build Doctor Trust

OSLO, Norway – January 27, 2026 – As artificial intelligence continues its rapid integration into medicine, a critical challenge has emerged: balancing technological power with the practical needs of physicians. A European medical technology firm is tackling this head-on with a new AI system for colonoscopies designed not just to be more powerful, but significantly quieter and more transparent, aiming to win the trust of the doctors who use it.

Augere Medical today announced the commercial release of its PolypAID™ software module 1.9, an update that introduces novel features to reduce physician distractions and clarify the AI’s decision-making process during real-time cancer screening. The release signals a maturing of medical AI, moving beyond the simple race for detection to focus on usability and building a symbiotic relationship between doctor and machine.

The Challenge of a 'Chatty' AI

For endoscopists performing back-to-back colonoscopies, the promise of AI has been a second set of eyes to help spot potentially cancerous polyps. Systems from major players like Medtronic, Fujifilm, and Olympus have demonstrated an ability to increase the adenoma detection rate (ADR), a key metric in preventing colorectal cancer. Studies have shown AI assistance can improve ADR by over 8% and slash the rate of missed polyps by half.

However, this benefit has often come with a significant drawback: “alert fatigue.” Early-generation AI systems, in their zealous quest to miss nothing, can produce a constant stream of alerts, flagging benign tissue, folds in the colon, or even bubbles. For a physician trying to concentrate, these frequent and often unnecessary interruptions can be more of a hindrance than a help.

“Endoscopists tell us they want the benefits of a highly sensitive AI for adenoma detection, but not at the price of constant, unnecessary alerts,” said Jon H. Hoem, CEO at Augere, in a statement. “This release is designed to make AI support feel calmer and more usable during back-to-back procedures, especially in busy European screening units.”

Augere’s solution is an advanced false-positive reduction filter. The company claims the new software increases framewise sensitivity—the ability to detect a polyp in a single video frame—by over 20% compared to its previous version, while simultaneously maintaining a very low rate of false alarms. This refinement is critical. An independent comparative study of several computer-aided detection systems found that while some achieved high sensitivity, it often came with a higher rate of false positives. In that study, Augere’s system in its “balanced” setting demonstrated the lowest false positive rate of the group at just 1.2%, a figure the company has worked to preserve even while boosting sensitivity.

Building Trust Through Transparency

Beyond just quieting the system, Augere is addressing a more profound issue in clinical AI: trust. The “black box” problem, where an AI provides a recommendation without explanation, has been a major barrier to adoption. Physicians are trained to understand the 'why' behind a diagnosis and are understandably hesitant to rely on a tool that cannot explain its reasoning.

Module 1.9 introduces a unique feature called the “Confidence Indicator.” This tool provides the endoscopist with a real-time visual cue of the AI’s certainty about a detected lesion. Instead of a simple binary “polyp/no polyp” alert, the physician gets a nuanced piece of data, allowing them to better gauge how much weight to give the AI’s suggestion.

“Transparency is no longer optional for clinical AI,” commented Pia H. Smedsrud, Augere’s Chief Medical Officer. “Showing confidence in an intuitive way gives physicians an immediate sense of how much weight to put on each alert, while keeping the final decision strictly with the endoscopists.”

This focus on transparency and physician control is particularly salient in Europe. The new software was developed with a keen eye on the stringent European Medical Device Regulation (MDR), which Augere secured for its PolypAID™ system in 2024. The MDR and influential bodies like the European Society of Gastrointestinal Endoscopy (ESGE) place a heavy emphasis on clinical safety, performance, and mitigating AI-related harms like increased procedure time or distraction. By designing a system that aligns with these principles, Augere is not just building a better tool, but one that is more likely to be accepted and integrated into the continent's highly regulated healthcare systems.

Navigating a Competitive and Regulated Market

Founded in 2018, Augere Medical has pursued a deliberate strategy focused on the European market. Backed by Norwegian investors like AM Equity and MP Pensjon, and supported by public grants from Innovation Norway, the company has raised approximately $6.6 million (NOK 73 million) to fuel its development and commercialization efforts.

This focused approach allows the company to tailor its product to a specific set of clinical and regulatory demands, positioning itself as a specialist in a market populated by global giants. The recent funding of €1.9 million is earmarked to strengthen its European sales and marketing teams and to continue its close collaboration with leading research institutions like Simula Research Laboratory and major hospitals in Oslo and Gothenburg.

The new software version will begin its rollout in selected European markets in the first quarter of 2026. This methodical launch, coupled with the company's stated plans to prepare for regulatory processes in other large international markets, suggests a long-term vision. By proving its technology in the demanding European environment, Augere can build a strong foundation for future global expansion.

Ultimately, the success of any medical AI rests on its ability to improve patient care. By reducing the number of missed polyps—the precursors to colorectal cancer—the technology has a direct and life-saving impact. The refinement of these systems, moving from simple detection to intelligent, trusted assistance, represents a crucial step forward. Augere’s tagline, “Confidence in outcomes™,” is meant to resonate with physicians needing reliable tools and with patients who depend on the most accurate screening possible. This new software aims to deliver on that promise by ensuring the AI in the room is not a noisy distraction, but a calm, transparent, and trusted partner in the fight against cancer.